You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

  1. PLASMA & BIOTHERAPIES - 11-01-2021

    CARES10 clinical trial: last patient treated in the USA

    Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients

    read more 

  2. PLASMA & BIOTHERAPIES - 21-08-2020

    First and Only US Pediatric human rabies Immune globulin Trial

    Kedrion-Kamada Announce Study Met Its Primary Objective

    read more 

  3. PLASMA & BIOTHERAPIES - 20-06-2019

    First patient enrolled and treated in Kedrion’s CARES10 clinical study

    Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

    read more 

  4. PLASMA & BIOTHERAPIES - 22-03-2017

    Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”

    International medical journal hosts review of contract plasma fractionation dynamics

    read more 

Pages

For more information please contact: pressoffice@kedrion.com